| 1 | DICER1 associated cervical embryonal rhabdomyosarcoma in a 59-year-old woman | 0.4 | 1 | Citations (PDF) |
| 2 | Ineffectiveness of Sotatercept Therapy in a Patient With Heritable Pulmonary Arterial Hypertension Associated With a Previously Unreported Missense Variant in GDF2, the Gene for Bone Morphogenic Protein-9Chest, 2025, 167, e37-e39 | 0.8 | 4 | Citations (PDF) |
| 3 | The Association Between Endometriosis And Ovarian Cancer Risk In Women With A Pathogenic Variant In BRCA1 Or BRCA2: A Case-Control Study | 2.2 | 0 | Citations (PDF) |
| 4 | Chemotherapy receipt in affected BRCA1/2 and PALB2 carriers with operable breast cancer: the impact of early detection and pre-diagnostic awareness on clinical outcomes and treatment | 1.4 | 2 | Citations (PDF) |
| 5 | Inherited Susceptibility to Cancer: Past, Present and Future | 1.0 | 10 | Citations (PDF) |
| 6 | Fetal Type Morphologies Suggest the Presence of DICER1 Hotspot Mutations in Non–small Cell Lung Cancer | 2.3 | 6 | Citations (PDF) |
| 7 | Teratoma‐associated and so‐called pure Wilms tumour of the ovary represent two separate tumour types with distinct molecular features | 2.6 | 6 | Citations (PDF) |
| 8 | Counselling Framework for Germline BRCA1/2 and PALB2 Carriers Considering Risk-Reducing Mastectomy | 2.0 | 7 | Citations (PDF) |
| 9 | SMARCB1 (INI1) Deficient Tumours of the Uterine Cervix: Report of Two Cases, Including One Associated With an NTRK Fusion | 1.1 | 6 | Citations (PDF) |
| 10 | Founder pathogenic variants in colorectal neoplasia susceptibility genes in Ashkenazi Jews undergoing colonoscopy | 1.4 | 0 | Citations (PDF) |
| 11 | A Validated Highly Sensitive Microsatellite Instability Assay Accurately Identifies Individuals Harboring Biallelic Germline PMS2 Pathogenic Variants in Constitutional Mismatch Repair Deficiency | 0.6 | 5 | Citations (PDF) |
| 12 | Estrogen Receptor Expression in DICER1-related Lesions is Associated With the Presence of Cystic Components | 2.3 | 3 | Citations (PDF) |
| 13 | Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy | 0.9 | 15 | Citations (PDF) |
| 14 | Intrathyroid Thymic Tissue in Children with DICER1 Syndrome | 6.7 | 0 | Citations (PDF) |
| 15 | Evoked piloerection sign/pseudo-Darier sign: A clinical clue to the diagnosis of cutaneous leiomyomas | 1.5 | 1 | Citations (PDF) |
| 16 | Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers | 3.2 | 9 | Citations (PDF) |
| 17 | Probing the relevance of BRCA1 and BRCA2 germline pathogenic variants beyond breast and ovarian cancer | 3.2 | 4 | Citations (PDF) |
| 18 | Reply to Letter by Cyrta et al, Entitled “Additional Considerations on Aberrant BRG1 (SMARCA4) Expression in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)” | 2.3 | 2 | Citations (PDF) |
| 19 | This is not Lynch syndrome: lessons from misattributed diagnoses in constitutional mismatch repair deficiency | 0.8 | 0 | Citations (PDF) |
| 20 | miRNA biogenesis and inherited disorders: clinico-molecular insights | 5.5 | 59 | Citations (PDF) |
| 21 | Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases | 1.7 | 13 | Citations (PDF) |
| 22 | Genomic characterization of DICER1-associated neoplasms uncovers molecular classes | 10.8 | 60 | Citations (PDF) |
| 23 | DICER1 platform domain missense variants inhibit miRNA biogenesis and lead to tumor susceptibility | 2.5 | 4 | Citations (PDF) |
| 24 | Unusual Aspects of Small Cell Carcinoma of the Ovary of Hypercalcaemic Type | 2.3 | 14 | Citations (PDF) |
| 25 | Germline EGFR c.2527G > A (p.V843I) variant and familial lung cancer | 1.8 | 5 | Citations (PDF) |
| 26 | Performance of the eHealth decision support tool, MIPOGG, for recognising children with Li-Fraumeni, DICER1, Constitutional mismatch repair deficiency and Gorlin syndromes | 2.2 | 5 | Citations (PDF) |
| 27 | A systematic review of the prevalence of pathogenic or likely pathogenic germline variants in individuals with FOXO1 fusion‐positive rhabdomyosarcoma | 0.9 | 2 | Citations (PDF) |
| 28 | Disturbed sleep is associated with reduced verbal episodic memory and entorhinal cortex volume in younger middle-aged women with risk-reducing early ovarian removal | 2.8 | 9 | Citations (PDF) |
| 29 | “I just wanted more”: Hereditary cancer syndromes patients’ perspectives on the utility of circulating tumour DNA testing for cancer screening | 2.1 | 5 | Citations (PDF) |
| 30 | Functional and phenotypic consequences of an unusual inversion in MSH2 | 1.1 | 0 | Citations (PDF) |
| 31 | Awareness and Candidacy for Endocrine Prevention and Risk Reducing Mastectomy in Unaffected High-Risk Women Referred for Breast Cancer Risk Assessment | 1.7 | 2 | Citations (PDF) |
| 32 | Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a
BRCA1
or
BRCA2
Mutation | 2.1 | 1 | Citations (PDF) |
| 33 | Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group | 2.2 | 120 | Citations (PDF) |
| 34 | Data sharing to improve concordance in variant interpretation across laboratories: results from the Canadian Open Genetics Repository | 2.2 | 35 | Citations (PDF) |
| 35 | An Unusual Enteric Yolk Sac Tumor: First Report of an Ovarian Germ Cell Tumor Associated With a Germline Pathogenic Variant in DICER1 | 1.1 | 8 | Citations (PDF) |
| 36 | Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation | 2.3 | 26 | Citations (PDF) |
| 37 | The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele
BRCA2
6174delT
| 1.5 | 5 | Citations (PDF) |
| 38 | PRAME protein expression in DICER1‐related tumours | 2.1 | 13 | Citations (PDF) |
| 39 | Neuroectodermal elements are part of the morphological spectrum of DICER1-associated neoplasms | 1.7 | 18 | Citations (PDF) |
| 40 | A decade of
RAD51C
and
RAD51D
germline variants in cancer | 1.0 | 21 | Citations (PDF) |
| 41 | Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants | 1.8 | 7 | Citations (PDF) |
| 42 | Bilateral Oophorectomy and the Risk of Breast Cancer in
BRCA1
Mutation Carriers: A Reappraisal | 0.6 | 8 | Citations (PDF) |
| 43 | The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population | 2.7 | 10 | Citations (PDF) |
| 44 | Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma | 1.7 | 15 | Citations (PDF) |
| 45 | Scene memory and hippocampal volume in middle-aged women with early hormone loss | 2.4 | 30 | Citations (PDF) |
| 46 | Patient Experience with a Gynecologic Oncology-Initiated Genetic Testing Model for Women with Tubo-Ovarian Cancer | 2.0 | 3 | Citations (PDF) |
| 47 | Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated? | 1.7 | 20 | Citations (PDF) |
| 48 | Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions | 4.0 | 21 | Citations (PDF) |
| 49 | The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes | 1.6 | 10 | Citations (PDF) |
| 50 | Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention | 2.0 | 7 | Citations (PDF) |
| 51 | Germline Missense Variants in
CDC20
Result in Aberrant Mitotic Progression and Familial Cancer | 2.6 | 10 | Citations (PDF) |
| 52 | Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients | 1.7 | 6 | Citations (PDF) |
| 53 | Ultrasound features of multinodular goiter in DICER1 syndrome | 2.7 | 10 | Citations (PDF) |
| 54 | PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression | 10.8 | 25 | Citations (PDF) |
| 55 | DICER1‐associated embryonal rhabdomyosarcoma and adenosarcoma of the gynecologic tract: Pathology, molecular genetics, and indications for molecular testing | 1.7 | 65 | Citations (PDF) |
| 56 | Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition | 1.2 | 12 | Citations (PDF) |
| 57 | The genetic landscape of choroid plexus tumors in children and adults | 0.9 | 53 | Citations (PDF) |
| 58 | Clinical Outcomes and Complications of Pituitary Blastoma | 3.1 | 41 | Citations (PDF) |
| 59 | Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma | 1.2 | 1 | Citations (PDF) |
| 60 | Investigating the causal role of MRE11A p.E506* in breast and ovarian cancer | 2.7 | 9 | Citations (PDF) |
| 61 | Prevalence and Spectrum of DICER1 Mutations in Adult-onset Thyroid Nodules with Indeterminate Cytology | 3.1 | 50 | Citations (PDF) |
| 62 | Mismatch Repair Universal Screening of Endometrial Cancers (MUSE) in a Canadian Cohort | 2.0 | 12 | Citations (PDF) |
| 63 | Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers | 1.8 | 10 | Citations (PDF) |
| 64 | BRCA1/2 and Endometrial Cancer Risk: Implications for Management | 3.2 | 13 | Citations (PDF) |
| 65 | Achieving clinical success with BET inhibitors as anti-cancer agents | 4.1 | 336 | Citations (PDF) |
| 66 | Clinical practice guidelines for BRCA1 and BRCA2 genetic testing | 2.8 | 152 | Citations (PDF) |
| 67 | Molecular characterization of DICER1-mutated pituitary blastoma | 5.8 | 32 | Citations (PDF) |
| 68 | Typical 22q11.2 deletion syndrome appears to confer a reduced risk of schwannoma | 3.3 | 8 | Citations (PDF) |
| 69 | DICER1-associated sarcomas at different sites exhibit morphological overlap arguing for a unified nomenclature | 1.9 | 15 | Citations (PDF) |
| 70 | Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) | 3.3 | 75 | Citations (PDF) |
| 71 | Embryonal rhabdomyosarcoma of the uterine corpus: a clinicopathological and molecular analysis of 21 cases highlighting a frequent association with DICER1 mutations | 3.8 | 43 | Citations (PDF) |
| 72 | Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant | 0.8 | 8 | Citations (PDF) |
| 73 | An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool | 2.7 | 3 | Citations (PDF) |
| 74 | Li-Fraumeni Syndrome in the Cancer Genomics Era | 3.2 | 6 | Citations (PDF) |
| 75 | A full molecular picture of F8 intron 1 inversion created with optical genome mapping | 1.3 | 7 | Citations (PDF) |
| 76 | Letter to the Editor:
Prevalence of
WWP1
Gene Mutations in Patients with Thyroid Nodules | 3.0 | 1 | Citations (PDF) |
| 77 | Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families | 4.7 | 7 | Citations (PDF) |
| 78 | Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers | 0.6 | 15 | Citations (PDF) |
| 79 | SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria | 10.8 | 73 | Citations (PDF) |
| 80 | Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa | 4.9 | 9 | Citations (PDF) |
| 81 | A novel mouse model of PMS2 founder mutation that causes mismatch repair defect due to aberrant splicing | 6.6 | 11 | Citations (PDF) |
| 82 | Mutations in BRCA-related breast and ovarian cancer in the South African Indian population: A descriptive study | 1.8 | 5 | Citations (PDF) |
| 83 | The Value of DICER1 Mutation Analysis in “Subtle” Diagnostically Challenging Embryonal Rhabdomyosarcomas of the Uterine Cervix | 1.1 | 21 | Citations (PDF) |
| 84 | Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes | 10.9 | 56 | Citations (PDF) |
| 85 | Companion Tumor Sequencing to Assess the Clinical Significance of Germline Sequencing in Children With Cancer | 5.2 | 12 | Citations (PDF) |
| 86 | Intrathyroidal Thymus (Incidentaloma) Mimicking Thyroid Neoplasia in DICER1 Syndrome | 0.8 | 2 | Citations (PDF) |
| 87 | A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene | 5.9 | 19 | Citations (PDF) |
| 88 | An eHealth decision‐support tool to prioritize referral practices for genetic evaluation of patients with Wilms tumor | 2.8 | 29 | Citations (PDF) |
| 89 | Macrofollicular Variant of Follicular Thyroid Carcinoma: A Rare Underappreciated Pitfall in the Diagnosis of Thyroid Carcinoma | 3.0 | 38 | Citations (PDF) |
| 90 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes | 14.1 | 171 | Citations (PDF) |
| 91 | Cancer Risks Associated With GermlinePALB2Pathogenic Variants: An International Study of 524 Families | 12.4 | 429 | Citations (PDF) |
| 92 | Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers? | 1.9 | 8 | Citations (PDF) |
| 93 | Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma | 3.8 | 67 | Citations (PDF) |
| 94 | Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation | 2.3 | 19 | Citations (PDF) |
| 95 | Etiologic Index — A Case-Only Measure of
BRCA1/2
–Associated Cancer Risk | 26.4 | 21 | Citations (PDF) |
| 96 | Bilateral Tumors — Inherited or Acquired? | 26.4 | 8 | Citations (PDF) |
| 97 | BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral | 2.2 | 26 | Citations (PDF) |
| 98 | Evaluation of molecular analysis in challenging ovarian sex cord-stromal tumours: a review of 50 cases | 1.4 | 20 | Citations (PDF) |
| 99 | A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer | 4.5 | 28 | Citations (PDF) |
| 100 | Olaparib for Metastatic Castration-Resistant Prostate Cancer | 26.4 | 19 | Citations (PDF) |
| 101 | Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers | 2.2 | 5 | Citations (PDF) |
| 102 | DICER1 screening in 15 paediatric paratesticular sarcomas unveils an unusual DICER1‐associated sarcoma | 2.1 | 17 | Citations (PDF) |
| 103 | The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer | 2.1 | 17 | Citations (PDF) |
| 104 | Malignant teratoid tumor of the thyroid gland: an aggressive primitive multiphenotypic malignancy showing organotypical elements and frequent DICER1 alterations—is the term “thyroblastoma” more appropriate? | 1.9 | 78 | Citations (PDF) |
| 105 | A child with neuroblastoma and metachronous anaplastic sarcoma of the kidney: Underlying DICER1 syndrome? | 0.9 | 6 | Citations (PDF) |
| 106 | SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors | 3.2 | 19 | Citations (PDF) |
| 107 | Cognitive markers of dementia risk in middle-aged women with bilateral salpingo-oophorectomy prior to menopause | 2.4 | 48 | Citations (PDF) |
| 108 | Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups | 2.7 | 26 | Citations (PDF) |
| 109 | Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D | 3.2 | 160 | Citations (PDF) |
| 110 | Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations | 3.8 | 147 | Citations (PDF) |
| 111 | Somatic tumour testing establishes that bilateral DICER1‐associated ovarian Sertoli–Leydig cell tumours represent independent primary neoplasms | 2.6 | 12 | Citations (PDF) |
| 112 | Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls | 2.7 | 30 | Citations (PDF) |
| 113 | Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines | 4.5 | 163 | Citations (PDF) |
| 114 | Cancer Immunoprevention: A Case Report Raising the Possibility of “Immuno-interception” | 1.2 | 11 | Citations (PDF) |
| 115 | DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor | 3.8 | 72 | Citations (PDF) |
| 116 | DICER1-associated sarcomas: towards a unified nomenclature | 3.8 | 32 | Citations (PDF) |
| 117 | Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases | 5.8 | 88 | Citations (PDF) |
| 118 | Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming | 20.8 | 336 | Citations (PDF) |
| 119 | Embryonal Rhabdomyosarcoma of the Ovary and Fallopian Tube | 2.3 | 62 | Citations (PDF) |
| 120 | DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis | 6.6 | 62 | Citations (PDF) |
| 121 | Deletion of Yy1 in mouse lung epithelium unveils molecular mechanisms governing pleuropulmonary blastoma pathogenesis | 1.2 | 9 | Citations (PDF) |
| 122 | RARE-17. SURVIVAL BENEFIT FOR INDIVIDUALS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME AND BRAIN TUMORS WHO UNDERGO SURVEILLANCE PROTOCOL. A REPORT FROM THE INTERNATIONAL REPLICATION REPAIR CONSORTIUM | 0.9 | 0 | Citations (PDF) |
| 123 | RARE-22. GERMLINE PATHOGENIC VARIANT c.1552G>A;p.E518K IN DGCR8 CONFERS SUSCEPTIBILITY FOR SCHWANNOMATOSIS AND THYROID TUMORS | 0.9 | 0 | Citations (PDF) |
| 124 | SAT-LB302 From Urolithiasis to Genetic Testing: An Unusual Presentation of MEN-4 Syndrome | 0.2 | 0 | Citations (PDF) |
| 125 | Homologous recombination DNA repair defects in PALB2-associated breast cancers | 4.7 | 50 | Citations (PDF) |
| 126 | Ten years of
DICER1
mutations: Provenance, distribution, and associated phenotypes | 1.0 | 139 | Citations (PDF) |
| 127 | Imaging of DICER1 syndrome | 1.3 | 48 | Citations (PDF) |
| 128 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer | 4.7 | 45 | Citations (PDF) |
| 129 | Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer | 1.6 | 24 | Citations (PDF) |
| 130 | eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer | 1.2 | 39 | Citations (PDF) |
| 131 | Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers | 1.1 | 233 | Citations (PDF) |
| 132 | Oestrogen receptor status and survival in women with BRCA2-associated breast cancer | 4.1 | 34 | Citations (PDF) |
| 133 | CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary | 10.8 | 112 | Citations (PDF) |
| 134 | SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer | 10.8 | 183 | Citations (PDF) |
| 135 | BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry | 1.0 | 39 | Citations (PDF) |
| 136 | Mesenchymal Hamartoma of the Liver and DICER1 Syndrome | 26.4 | 62 | Citations (PDF) |
| 137 | SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors | 2.6 | 66 | Citations (PDF) |
| 138 | The dilemma of early preventive oophorectomy in familial small cell carcinoma of the ovary of hypercalcemic type | 0.4 | 19 | Citations (PDF) |
| 139 | Case 35-2018: A Woman with Back Pain and a Remote History of Breast Cancer | 26.4 | 0 | Citations (PDF) |
| 140 | A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytes | 1.0 | 49 | Citations (PDF) |
| 141 | Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype | 28.4 | 172 | Citations (PDF) |
| 142 | Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers | 1.8 | 16 | Citations (PDF) |
| 143 | Une immunodéficience combinée causée par une mutation du gène ICOSLG | 0.2 | 0 | Citations (PDF) |
| 144 | Further evidence that full gene deletions of DICER1 predispose to DICER1 syndrome | 1.7 | 10 | Citations (PDF) |
| 145 | Expanding the morphological spectrum of ovarian microcystic stromal tumour | 2.6 | 28 | Citations (PDF) |
| 146 | Clinical and Molecular Characteristics May Alter Treatment Strategies of Thyroid Malignancies in DICER1 Syndrome | 3.1 | 35 | Citations (PDF) |
| 147 | An update on the central nervous system manifestations of DICER1 syndrome | 5.8 | 108 | Citations (PDF) |
| 148 | Survey of primary care physicians’ views about breast and ovarian cancer screening for true BRCA1/2 non-carriers | 0.9 | 1 | Citations (PDF) |
| 149 | DICER1 Mutations Are Frequent in Adolescent-Onset Papillary Thyroid Carcinoma | 3.1 | 113 | Citations (PDF) |
| 150 | Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices | 2.8 | 58 | Citations (PDF) |
| 151 | Analysis of
DICER1
in familial and sporadic cases of transposition of the great arteries | 0.0 | 3 | Citations (PDF) |
| 152 | Atypical tuberous sclerosis complex presenting as familial renal cell carcinoma with leiomyomatous stroma | 2.1 | 11 | Citations (PDF) |
| 153 | A novel DICER1 mutation in familial multinodular goitre | 1.5 | 6 | Citations (PDF) |
| 154 | Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers | 10.9 | 171 | Citations (PDF) |
| 155 | GATA2 Deficiency Due to de Novo Complete Monoallelic Deletion in an Adolescent With Myelodysplasia | 0.5 | 5 | Citations (PDF) |
| 156 | Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers | 1.8 | 29 | Citations (PDF) |
| 157 | Hereditary SWI/SNF complex deficiency syndromes | 1.8 | 64 | Citations (PDF) |
| 158 | Thorough in silico and in vitro cDNA analysis of 21 putativeBRCA1andBRCA2splice variants and a complex tandem duplication inBRCA2allowing the identification of activated cryptic splice donor sites inBRCA2exon 11 | 1.0 | 6 | Citations (PDF) |
| 159 | Multiple DICER1‐related tumors in a child with a large interstitial 14q32 deletion | 1.7 | 42 | Citations (PDF) |
| 160 | Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition | 4.1 | 18 | Citations (PDF) |
| 161 | Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers | 2.8 | 16 | Citations (PDF) |
| 162 | Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR) | 3.3 | 31 | Citations (PDF) |
| 163 | Ovarian Microcystic Stromal Tumors Are Characterized by Alterations in the Beta-Catenin-APC Pathway and May be an Extracolonic Manifestation of Familial Adenomatous Polyposis | 2.3 | 50 | Citations (PDF) |
| 164 | TBIO-25. CHOROID PLEXUS PAPILLOMAS IN FAMILIES WITH DICER1 MUTATION ASSOCIATED DISEASE | 0.9 | 0 | Citations (PDF) |
| 165 | SMO Syndrome: A Unifying Molecular Diagnosis That Suggests Therapeutic Opportunities | 1.1 | 2 | Citations (PDF) |
| 166 | Loss of human ICOSL results in combined immunodeficiency | 5.9 | 58 | Citations (PDF) |
| 167 | Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome | 14.1 | 213 | Citations (PDF) |
| 168 | Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation | 2.3 | 97 | Citations (PDF) |
| 169 | Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers | 1.8 | 12 | Citations (PDF) |
| 170 | Revisiting pleuropulmonary blastoma and atypical choroid plexus papilloma in a young child: DICER1 syndrome or not? | 0.9 | 7 | Citations (PDF) |
| 171 | Retrospective evaluation of a decision‐support algorithm (MIPOGG) for genetic referrals for children with neuroblastic tumors | 0.9 | 27 | Citations (PDF) |
| 172 | Infantile Pulmonary Teratoid Tumor | 26.4 | 19 | Citations (PDF) |
| 173 | Ovarian small cell carcinoma in one of a pair of monozygous twins | 1.1 | 4 | Citations (PDF) |
| 174 | The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first‐degree relative with breast cancer | 1.5 | 20 | Citations (PDF) |
| 175 | Clinical, morphological and immunohistochemical evidence that small‐cell carcinoma of the ovary of hypercalcaemic type (SCCOHT) may be a primitive germ‐cell neoplasm | 2.6 | 52 | Citations (PDF) |
| 176 | Oncogenic role of PDK4 in human colon cancer cells | 4.1 | 110 | Citations (PDF) |
| 177 | gsSKAT: Rapid gene set analysis and multiple testing correction for rare‐variant association studies using weighted linear kernels | 2.4 | 9 | Citations (PDF) |
| 178 | Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer | 2.7 | 29 | Citations (PDF) |
| 179 | Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome | 4.5 | 180 | Citations (PDF) |
| 180 | PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood | 4.5 | 159 | Citations (PDF) |
| 181 | Sequencing of DICER1 in sarcomas identifies biallelic somatic DICER1 mutations in an adult-onset embryonal rhabdomyosarcoma | 4.1 | 35 | Citations (PDF) |
| 182 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer | 14.1 | 512 | Citations (PDF) |
| 183 | Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? | 2.3 | 42 | Citations (PDF) |
| 184 | Compromised BRCA1–PALB2 interaction is associated with breast cancer risk | 5.2 | 84 | Citations (PDF) |
| 185 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | 14.1 | 412 | Citations (PDF) |
| 186 | A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer | 14.1 | 530 | Citations (PDF) |
| 187 | Functionally Null
RAD51D
Missense Mutation Associates Strongly with Ovarian Carcinoma | 2.6 | 43 | Citations (PDF) |
| 188 | Retinoblastoma and Neuroblastoma Predisposition and Surveillance | 4.5 | 220 | Citations (PDF) |
| 189 | Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood | 4.5 | 115 | Citations (PDF) |
| 190 | DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors | 2.3 | 161 | Citations (PDF) |
| 191 | Genetics meets pathology – an increasingly important relationship | 3.2 | 10 | Citations (PDF) |
| 192 | Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers | 3.2 | 181 | Citations (PDF) |
| 193 | Breast cancer in systemic lupus | 1.0 | 28 | Citations (PDF) |
| 194 | No Evidence of Excessive Cancer Screening in Female Noncarriers from BRCA1/2 Mutation–Positive Families | 2.0 | 3 | Citations (PDF) |
| 195 | Anaplastic sarcomas of the kidney are characterized by DICER1 mutations | 3.8 | 79 | Citations (PDF) |
| 196 | Low yield of gastroscopy in patients with Lynch syndrome | 0.8 | 13 | Citations (PDF) |
| 197 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers | 1.5 | 12 | Citations (PDF) |
| 198 | Adult-Onset Cervical Embryonal Rhabdomyosarcoma and DICER1 Mutations | 1.4 | 28 | Citations (PDF) |
| 199 | Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case‐Control Sequencing Studies | 2.4 | 5 | Citations (PDF) |
| 200 | Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT) Commonly Exhibits Positivity With Sex Cord Markers FOXL2 and SF-1 but Lacks FOXL2 and DICER1 Mutations | 1.1 | 67 | Citations (PDF) |
| 201 | Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small‐cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics | 2.6 | 69 | Citations (PDF) |
| 202 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS | 2.2 | 210 | Citations (PDF) |
| 203 | Tumor progression in DICER1-mutated cystic nephroma—witnessing the genesis of anaplastic sarcoma of the kidney | 1.7 | 40 | Citations (PDF) |
| 204 | Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation | 3.3 | 6 | Citations (PDF) |
| 205 | Small-Cell Carcinoma of the Ovary of Hypercalcemic Type (Malignant Rhabdoid Tumor of the Ovary) | 0.9 | 64 | Citations (PDF) |
| 206 | The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type | 2.3 | 128 | Citations (PDF) |
| 207 | Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant | 4.0 | 254 | Citations (PDF) |
| 208 | SomaticDICER1mutations in adult-onset pulmonary blastoma | 6.5 | 30 | Citations (PDF) |
| 209 | Rare non-epithelial ovarian neoplasms: Pathology, genetics and treatment | 2.3 | 37 | Citations (PDF) |
| 210 | REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants | 4.0 | 2,942 | Citations (PDF) |
| 211 | Recently characterized molecular events in uncommon gynaecological neoplasms and their clinical importance | 2.6 | 20 | Citations (PDF) |
| 212 | Deep Sequencing Reveals Spatially Distributed Distinct Hot Spot Mutations in DICER1-Related Multinodular Goiter | 3.1 | 41 | Citations (PDF) |
| 213 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer | 10.8 | 103 | Citations (PDF) |
| 214 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus | 10.8 | 92 | Citations (PDF) |
| 215 | Germline and Somatic DICER1 Mutations in a Well-Differentiated Fetal Adenocarcinoma of the Lung | 1.5 | 40 | Citations (PDF) |
| 216 | Gynecologic Manifestations of the DICER1 Syndrome | 0.9 | 49 | Citations (PDF) |
| 217 | Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study | 1.8 | 68 | Citations (PDF) |
| 218 | Impaired RASGRF1/ERK–mediated GM-CSF response characterizes CARD9 deficiency in French-Canadians | 4.4 | 101 | Citations (PDF) |
| 219 | Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors | 5.8 | 183 | Citations (PDF) |
| 220 | Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer | 6.5 | 53 | Citations (PDF) |
| 221 | Hereditary leiomyomatosis and renal cell cancer syndrome | 0.8 | 4 | Citations (PDF) |
| 222 | High-sensitivity sequencing reveals multi-organ somatic mosaicism causing DICER1 syndrome | 2.2 | 83 | Citations (PDF) |
| 223 | Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant | 12.4 | 7 | Citations (PDF) |
| 224 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 | 1.8 | 20 | Citations (PDF) |
| 225 | The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases | 1.1 | 28 | Citations (PDF) |
| 226 | Prophylactic oophorectomy for hereditary small cell carcinoma of the ovary, hypercalcemic type | 0.4 | 32 | Citations (PDF) |
| 227 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers | 3.4 | 28 | Citations (PDF) |
| 228 | Ovarian Sex Cord-Stromal Tumors in Patients With Probable or Confirmed Germline DICER1 Mutations | 1.1 | 44 | Citations (PDF) |
| 229 | Using a Family History Questionnaire to Identify Adult Patients with Increased Genetic Risk for Sarcoma | 2.0 | 18 | Citations (PDF) |
| 230 | Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers | 1.8 | 13 | Citations (PDF) |
| 231 | Biallelic NTHL1 Mutations in a Woman with Multiple Primary Tumors | 26.4 | 84 | Citations (PDF) |
| 232 | Primary rhabdoid tumor of the ovary: When large cells become small cells | 0.4 | 7 | Citations (PDF) |
| 233 | Establishing a Clinic-Based Pancreatic Cancer and Periampullary Tumour Research Registry in Quebec | 2.0 | 12 | Citations (PDF) |
| 234 | Germline RECQL mutations are associated with breast cancer susceptibility | 14.1 | 184 | Citations (PDF) |
| 235 | Effect of Oophorectomy on Survival After Breast Cancer inBRCA1andBRCA2Mutation Carriers | 10.9 | 128 | Citations (PDF) |
| 236 | Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci | 0.6 | 59 | Citations (PDF) |
| 237 | Psychosocial Impact of Lynch Syndrome on Affected Individuals and Families | 1.5 | 21 | Citations (PDF) |
| 238 | Radiographic Screening of Infants and Young Children With Genetic Predisposition for Rare Malignancies: DICER1 Mutations and Pleuropulmonary Blastoma | 2.9 | 25 | Citations (PDF) |
| 239 | Ovarian embryonal rhabdomyosarcoma is a rare manifestation of the DICER1 syndrome | 1.7 | 56 | Citations (PDF) |
| 240 | Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers? | 1.8 | 9 | Citations (PDF) |
| 241 | Germline TP53 mutational spectrum in French Canadians with breast cancer | 1.8 | 23 | Citations (PDF) |
| 242 | ClinGen and Genetic Testing | 26.4 | 8 | Citations (PDF) |
| 243 | Weight Gain After Oophorectomy Among Women with a BRCA1 or BRCA2 Mutation | 1.0 | 2 | Citations (PDF) |
| 244 | Epithelial inactivation of Yy1 abrogates lung branching morphogenesis | 2.1 | 40 | Citations (PDF) |
| 245 | Population genetic testing for cancer susceptibility: founder mutations to genomes | 54.3 | 98 | Citations (PDF) |
| 246 | Germ-line and somatic DICER1 mutations in pineoblastoma | 5.8 | 166 | Citations (PDF) |
| 247 | Breast-Cancer Risk in Families with Mutations in PALB2 | 26.4 | 72 | Citations (PDF) |
| 248 | A Prior Diagnosis of Breast Cancer is a Risk Factor for Breast Cancer in Brca1 and Brca2 Carriers | 2.0 | 13 | Citations (PDF) |
| 249 | Serum levels of mature microRNAs in DICER1-mutated pleuropulmonary blastoma | 3.3 | 50 | Citations (PDF) |
| 250 | DICER1mutations in an adolescent with cervical embryonal rhabdomyosarcoma (cERMS) | 0.9 | 38 | Citations (PDF) |
| 251 | No small surprise – small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour | 3.2 | 122 | Citations (PDF) |
| 252 | Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada | 1.4 | 20 | Citations (PDF) |
| 253 | Breast-Cancer Risk in Families With Mutations in PALB2 | 0.4 | 1 | Citations (PDF) |
| 254 | The Histomorphology of Lynch Syndrome–associated Ovarian Carcinomas | 2.3 | 119 | Citations (PDF) |
| 255 | Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis | 0.2 | 272 | Citations (PDF) |
| 256 | Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study | 1.1 | 224 | Citations (PDF) |
| 257 | Multinodular Goiter in Children: An Important Pointer to a Germline DICER1 Mutation | 3.1 | 35 | Citations (PDF) |
| 258 | Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type | 14.1 | 476 | Citations (PDF) |
| 259 | Cultural Aspects of Healthy BRCA Carriers From Two Ethnocultural Groups | 1.6 | 19 | Citations (PDF) |
| 260 | DICER1: mutations, microRNAs and mechanisms | 34.5 | 526 | Citations (PDF) |
| 261 | CARD9 Deficiency and Spontaneous Central Nervous System Candidiasis: Complete Clinical Remission With GM-CSF Therapy | 3.7 | 173 | Citations (PDF) |
| 262 | Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study | 1.8 | 28 | Citations (PDF) |
| 263 | Breast-Cancer Risk in Families with Mutations in
PALB2 | 26.4 | 845 | Citations (PDF) |
| 264 | SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis | 5.8 | 194 | Citations (PDF) |
| 265 | Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations | 5.8 | 250 | Citations (PDF) |
| 266 | Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers | 1.8 | 41 | Citations (PDF) |
| 267 | Exploring the Association BetweenDICER1Mutations and Differentiated Thyroid Carcinoma | 3.1 | 129 | Citations (PDF) |
| 268 | Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration | 3.4 | 216 | Citations (PDF) |
| 269 | Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient | 2.1 | 14 | Citations (PDF) |
| 270 | DICER1 hotspot mutations in non-epithelial gonadal tumours | 4.1 | 127 | Citations (PDF) |
| 271 | Hi-Plex for high-throughput mutation screening: application to the breast cancer susceptibility gene PALB2 | 1.3 | 17 | Citations (PDF) |
| 272 | The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation | 1.8 | 70 | Citations (PDF) |
| 273 | The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study | 2.3 | 118 | Citations (PDF) |
| 274 | Familial rhabdoid tumour 'avant la lettre'—from pathology review to exome sequencing and back again | 3.2 | 64 | Citations (PDF) |
| 275 | Contribution of the PALB2 c.2323C>T [p.Q775X] Founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent | 1.8 | 27 | Citations (PDF) |
| 276 | Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation | 2.2 | 135 | Citations (PDF) |
| 277 | Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three‐dimensional nuclear organization of patient‐derived cell lines | 1.7 | 7 | Citations (PDF) |
| 278 | Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? | 1.8 | 31 | Citations (PDF) |
| 279 | Hereditary Colorectal Cancer Registries in Canada: Report from the Colorectal Cancer Association of Canada Consensus Meeting; Montreal, Quebec; October 28, 2011 | 2.0 | 6 | Citations (PDF) |
| 280 | Biallelic Deleterious
BRCA1
Mutations in a Woman with Early-Onset Ovarian Cancer | 6.8 | 135 | Citations (PDF) |
| 281 | Germ-line and somaticDICER1mutations in a pleuropulmonary blastoma | 0.9 | 34 | Citations (PDF) |
| 282 | The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial | 2.2 | 53 | Citations (PDF) |
| 283 | Biallelic DICER1 mutations occur in Wilms tumours | 3.2 | 143 | Citations (PDF) |
| 284 | Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease | 1.8 | 24 | Citations (PDF) |
| 285 | Life insurance: genomic stratification and risk classification | 2.1 | 49 | Citations (PDF) |
| 286 | Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study | 4.1 | 134 | Citations (PDF) |
| 287 | Germline DICER1 mutation and associated loss of heterozygosity in a pineoblastoma: Figure 1 | 2.2 | 66 | Citations (PDF) |
| 288 | Oophorectomy after Menopause and the Risk of Breast Cancer in
BRCA1
and
BRCA2
Mutation Carriers | 0.6 | 49 | Citations (PDF) |
| 289 | Recurrent SomaticDICER1Mutations in Nonepithelial Ovarian Cancers | 26.4 | 469 | Citations (PDF) |
| 290 | The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers | 4.1 | 246 | Citations (PDF) |
| 291 | Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families | 4.1 | 46 | Citations (PDF) |
| 292 | PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2 | 4.1 | 189 | Citations (PDF) |
| 293 | Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers | 2.8 | 10 | Citations (PDF) |
| 294 | Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers | 3.4 | 117 | Citations (PDF) |
| 295 | Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families | 1.8 | 6 | Citations (PDF) |
| 296 | CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer | 3.4 | 425 | Citations (PDF) |
| 297 | A whole‐genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor‐negative and ‐positive breast cancers | 3.2 | 63 | Citations (PDF) |
| 298 | Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG | 1.6 | 14 | Citations (PDF) |
| 299 | The risk of breast cancer in women with a BRCA1 mutation from North America and Poland | 2.8 | 44 | Citations (PDF) |
| 300 | Reading Between the Lines: A Comparison of Responders and Non‐responders to a Family History Questionnaire and Implications for Cancer Genetic Counselling | 1.8 | 7 | Citations (PDF) |
| 301 | A founder BRCA2 mutation in non‐Afrikaner breast cancer patients of the Western Cape of South Africa | 1.5 | 29 | Citations (PDF) |
| 302 | Rare germline mutations inPALB2and breast cancer risk: A population-based study | 1.0 | 80 | Citations (PDF) |
| 303 | HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG) | 1.8 | 182 | Citations (PDF) |
| 304 | Genetic architecture of prostate cancer in the Ashkenazi Jewish population | 4.1 | 12 | Citations (PDF) |
| 305 | The Effect of a DNA Repair Gene on Cellular Invasiveness: Xrcc3 Over-Expression in Breast Cancer Cells | 1.5 | 20 | Citations (PDF) |
| 306 | Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome | 1.5 | 32 | Citations (PDF) |
| 307 | Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade | 2.6 | 106 | Citations (PDF) |
| 308 | Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis | 4.1 | 92 | Citations (PDF) |
| 309 | Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers | 4.1 | 214 | Citations (PDF) |
| 310 | A survey of APC mutations in Quebec | 1.1 | 11 | Citations (PDF) |
| 311 | Inherited Mutations in Breast Cancer Genes—Risk and Response | 1.6 | 58 | Citations (PDF) |
| 312 | Qualitative thematic analysis of consent forms used in cancer genome sequencing | 1.7 | 24 | Citations (PDF) |
| 313 | Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines | 1.3 | 44 | Citations (PDF) |
| 314 | Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations | 2.7 | 76 | Citations (PDF) |
| 315 | <emph type="ital">DICER1</emph> Mutations in Familial Multinodular Goiter With and Without Ovarian Sertoli-Leydig Cell Tumors | 14.4 | 326 | Citations (PDF) |
| 316 | Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG) | 1.8 | 21 | Citations (PDF) |
| 317 | Vascular proliferation is a prognostic factor in breast cancer | 1.8 | 34 | Citations (PDF) |
| 318 | Is Breast Cancer the Same Disease in Asian and Western Countries? | 1.2 | 534 | Citations (PDF) |
| 319 | BRCA1 and BRCA2 families and the risk of skin cancer | 1.1 | 34 | Citations (PDF) |
| 320 | Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers | 0.9 | 27 | Citations (PDF) |
| 321 | Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma | 0.7 | 14 | Citations (PDF) |
| 322 | How old is this mutation? - a study of three Ashkenazi Jewish founder mutations | 2.8 | 21 | Citations (PDF) |
| 323 | Genome‐wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for prostate cancer Genetics using novel sumLINK and sumLOD analyses | 1.6 | 24 | Citations (PDF) |
| 324 | Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations | 3.2 | 100 | Citations (PDF) |
| 325 | Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study | 4.5 | 394 | Citations (PDF) |
| 326 | Neonatal Gardner Fibroma: A Sentinel Presentation of Severe Familial Adenomatous Polyposis | 2.9 | 21 | Citations (PDF) |
| 327 | Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies | 4.6 | 836 | Citations (PDF) |
| 328 | Traffic Control for BRCA1 | 26.4 | 10 | Citations (PDF) |
| 329 | Mutation analysis of the gene encoding the PALB2-binding protein MRG15 in BRCA1/2-negative breast cancer families | 1.3 | 6 | Citations (PDF) |
| 330 | Triple-Negative Breast Cancer | 26.4 | 3,969 | Citations (PDF) |
| 331 | Homozygous
BUB1B
Mutation and Susceptibility to Gastrointestinal Neoplasia | 26.4 | 91 | Citations (PDF) |
| 332 | Tumor size and survival in breast cancer—a reappraisal | 54.3 | 118 | Citations (PDF) |
| 333 | A PALB2 mutation associated with high risk of breast cancer | 3.4 | 109 | Citations (PDF) |
| 334 | Colonic or coelomic? | 46.9 | 0 | Citations (PDF) |
| 335 | RAD51C germline mutations in breast and ovarian cancer patients | 3.4 | 51 | Citations (PDF) |
| 336 | A genome-wide analysis of loss of heterozygosity and chromosomal copy number variation in Proteus syndrome using high-density SNP microarrays | 1.3 | 4 | Citations (PDF) |
| 337 | On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations | 2.1 | 124 | Citations (PDF) |
| 338 | International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation | 1.8 | 33 | Citations (PDF) |
| 339 | Clinical Implications of Next-Generation Sequencing for Cancer Medicine | 2.0 | 11 | Citations (PDF) |
| 340 | Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer | 1.3 | 31 | Citations (PDF) |
| 341 | High frequency of exon deletions and putative founder effects in French Canadian Lynch syndrome families | 1.0 | 15 | Citations (PDF) |
| 342 | Functional redundancy of exon 12 ofBRCA2revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant | 1.0 | 34 | Citations (PDF) |
| 343 | Long‐term outcome after neo‐adjuvant chemotherapy for breast cancer in BRCA1/2 carriers | 2.8 | 10 | Citations (PDF) |
| 344 | Identification of seven new prostate cancer susceptibility loci through a genome-wide association study | 14.1 | 403 | Citations (PDF) |
| 345 | The contribution of founder mutations to early‐onset breast cancer in French‐Canadian women | 1.5 | 43 | Citations (PDF) |
| 346 | Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers | 1.8 | 38 | Citations (PDF) |
| 347 | Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case–control study | 1.2 | 98 | Citations (PDF) |
| 348 | Hereditary breast cancer: new genetic developments, new therapeutic avenues | 1.8 | 295 | Citations (PDF) |
| 349 | Analysis of the gene coding for the BRCA2‐Interacting protein PALB2 in hereditary prostate cancer | 1.6 | 38 | Citations (PDF) |
| 350 | Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance | 1.0 | 56 | Citations (PDF) |
| 351 | International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers | 2.8 | 324 | Citations (PDF) |
| 352 | Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach | 2.1 | 43 | Citations (PDF) |
| 353 | Rapid progression of prostate cancer in men with a BRCA2 mutation | 4.1 | 149 | Citations (PDF) |
| 354 | Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation | 1.5 | 54 | Citations (PDF) |
| 355 | Synchronous occult cancers of the endometrium and fallopian tube in an MSH2 mutation carrier at time of prophylactic surgery | 2.3 | 25 | Citations (PDF) |
| 356 | Identification of a novel CHEK2variant and assessment of its contribution to the risk of breast cancer in French Canadian women | 2.1 | 16 | Citations (PDF) |
| 357 | Meta-analysis and pooled analysis of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: a HuGE-GSEC review | 3.3 | 60 | Citations (PDF) |
| 358 | Inherited Susceptibility to Common Cancers | 26.4 | 504 | Citations (PDF) |
| 359 | The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype | 1.7 | 43 | Citations (PDF) |
| 360 | Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer | 6.5 | 22 | Citations (PDF) |
| 361 | Triple-Negative Breast Cancer: Risk Factors to Potential Targets | 4.5 | 391 | Citations (PDF) |
| 362 | Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group | 12.4 | 169 | Citations (PDF) |
| 363 | BRCA1 mutations contribute to cell motility and invasion by affecting its main regulators | 2.3 | 21 | Citations (PDF) |
| 364 | Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium | 0.6 | 152 | Citations (PDF) |
| 365 | Sporadic desmoid tumor in an Ashkenazi patient homozygous for theAPC*I1307Kgene mutation | 1.7 | 4 | Citations (PDF) |
| 366 | PALB2/FANCN, acteur dans la prédisposition au cancer du sein ? | 0.2 | 0 | Citations (PDF) |
| 367 | Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update | 1.8 | 31 | Citations (PDF) |
| 368 | MSI-H colorectal cancers preferentially retain and expand intraepithelial lymphocytes rather than peripherally derived CD8+ T cells | 3.1 | 11 | Citations (PDF) |
| 369 | Analysis of PALB2/FANCN-associated breast cancer families | 5.2 | 202 | Citations (PDF) |
| 370 | Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics | 2.1 | 32 | Citations (PDF) |
| 371 | Sonographic Features of Breast Carcinoma Presenting as Masses inBRCAGene Mutation Carriers | 1.3 | 19 | Citations (PDF) |
| 372 | Mixed Ovarian Germ Cell Tumor in a BRCA2 Mutation Carrier | 1.1 | 12 | Citations (PDF) |
| 373 | Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study | 16.1 | 235 | Citations (PDF) |
| 374 | Are triple-negative tumours and basal-like breast cancer synonymous? | 3.4 | 101 | Citations (PDF) |
| 375 | Identification of a novel truncating PALB2mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women | 3.4 | 134 | Citations (PDF) |
| 376 | Use of immunohistochemical markers can refine prognosis in triple negative breast cancer | 2.1 | 322 | Citations (PDF) |
| 377 | Clinically Relevant Biology of Hereditary Breast Cancer | 2.8 | 13 | Citations (PDF) |
| 378 | Validation study of the lambda model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women | 1.5 | 12 | Citations (PDF) |
| 379 | Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers | 1.8 | 47 | Citations (PDF) |
| 380 | Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families | 1.8 | 33 | Citations (PDF) |
| 381 | Are triple negative tumours and basal-like breast cancer synonymous? | 3.4 | 8 | Citations (PDF) |
| 382 | Spontaneous and therapeutic abortions and the risk of breast cancer among BRCAmutation carriers | 3.4 | 49 | Citations (PDF) |
| 383 | Familial Adenomatous Polyposis | 0.7 | 631 | Citations (PDF) |
| 384 | Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics | 1.8 | 57 | Citations (PDF) |
| 385 | Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent | 1.5 | 29 | Citations (PDF) |
| 386 | The Basal Phenotype of BRCA1-Related Breast Cancer | 0.0 | 1 | Citations (PDF) |
| 387 | Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study | 16.1 | 106 | Citations (PDF) |
| 388 | The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations | 1.8 | 15 | Citations (PDF) |
| 389 | Haplotype analysis suggest common founders in carriers of the recurrent BRCA2mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families | 1.8 | 21 | Citations (PDF) |
| 390 | Multiple primary malignancies in a patient with situs ambiguus | 1.5 | 10 | Citations (PDF) |
| 391 | Transforming growth factor-beta pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes | 2.6 | 15 | Citations (PDF) |
| 392 | Muir Torre syndrome and MSH2 mutations: the importance of dermatological awareness | 4.1 | 2 | Citations (PDF) |
| 393 | The Value of Multi-Modal Gene Screening in HNPCC in Quebec: Three Mutations in Mismatch Repair Genes that would have not been Correctly Identified by Genomic DNA Sequencing Alone | 1.1 | 8 | Citations (PDF) |
| 394 | BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis | 1.1 | 128 | Citations (PDF) |
| 395 | Tumor Buds Show Reduced Expression of Laminin-5 Gamma 2 Chain in DNA Mismatch Repair Deficient Colorectal Cancer | 1.2 | 17 | Citations (PDF) |
| 396 | Distinct patterns of germ-line deletions inMLH1 andMSH2: the implication of Alu repetitive element in the genetic etiology of Lynch syndrome (HNPCC) | 1.0 | 50 | Citations (PDF) |
| 397 | Coffee consumption and breast cancer risk amongBRCA1 andBRCA2 mutation carriers | 2.8 | 78 | Citations (PDF) |
| 398 | Tamoxifen and contralateral breast cancer inBRCA1 andBRCA2 carriers: An update | 2.8 | 252 | Citations (PDF) |
| 399 | The Basal Phenotype of BRCA1-Related Breast Cancer: Past, Present and Future | 2.3 | 46 | Citations (PDF) |
| 400 | ALMNASplicing Mutation in Two Sisters with Severe Dunnigan-Type Familial Partial Lipodystrophy Type 2 | 3.1 | 47 | Citations (PDF) |
| 401 | Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation | 14.4 | 578 | Citations (PDF) |
| 402 | Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers | 1.4 | 2 | Citations (PDF) |
| 403 | Novel genomic insertion-deletion in MLH1: possible mechanistic role for non-homologous end-joining DNA repair | 1.5 | 8 | Citations (PDF) |
| 404 | The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers | 2.3 | 157 | Citations (PDF) |
| 405 | Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC) | 1.7 | 119 | Citations (PDF) |
| 406 | Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers | 2.8 | 164 | Citations (PDF) |
| 407 | Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms | 2.7 | 33 | Citations (PDF) |
| 408 | Double frameshift mutations in APC and MSH2 in the same individual | 1.5 | 14 | Citations (PDF) |
| 409 | Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers | 1.2 | 76 | Citations (PDF) |
| 410 | A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected Tumors | 0.6 | 198 | Citations (PDF) |
| 411 | Macrophage Scavenger Receptor 1 999C>T (R293X) Mutation and Risk of Prostate Cancer | 0.6 | 21 | Citations (PDF) |
| 412 | Immunohistochemical Expression of DNA Repair Proteins in Familial Breast Cancer Differentiate BRCA2-Associated Tumors | 12.4 | 71 | Citations (PDF) |
| 413 | A Comparison of Bilateral Breast Cancers in BRCA Carriers | 0.6 | 46 | Citations (PDF) |
| 414 | Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study | 12.4 | 417 | Citations (PDF) |
| 415 | Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment | 8.0 | 51 | Citations (PDF) |
| 416 | A Combined Genomewide Linkage Scan of 1,233 Families for Prostate Cancer–Susceptibility Genes Conducted by the International Consortium for Prostate Cancer Genetics | 4.0 | 138 | Citations (PDF) |
| 417 | BRCA2: breaks, mistakes and failed separations | 6.4 | 20 | Citations (PDF) |
| 418 | Title is missing! | 1.4 | 11 | Citations (PDF) |
| 419 | Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2mutation carriers | 3.4 | 106 | Citations (PDF) |
| 420 | Re: Estrogen Receptor Status of Primary Breast Cancer Is Predictive of Estrogen Receptor Status of Contralateral Breast Cancer | 3.2 | 2 | Citations (PDF) |
| 421 | Breast-feeding and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers | 3.2 | 185 | Citations (PDF) |
| 422 | Germline truncating mutations in both MSH2 and BRCA2 in a single kindred | 4.1 | 43 | Citations (PDF) |
| 423 | Putative common origin of two MLH1 mutations in Italian-Quebec hereditary non-polyposis colorectal cancer families | 1.5 | 8 | Citations (PDF) |
| 424 | BRCA1 and BRCA2: 1994 and beyond | 34.5 | 896 | Citations (PDF) |
| 425 | E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells | 5.2 | 108 | Citations (PDF) |
| 426 | Prevention and genetic testing for breast cancer: variations in medical decisions | 2.0 | 49 | Citations (PDF) |
| 427 | Mutation analysis of the tumor suppressorPTEN and the glypican 3 (GPC3) gene in patients diagnosed with Proteus syndrome | 0.5 | 32 | Citations (PDF) |
| 428 | Smoking and the risk of breast cancer among carriers of BRCA mutations | 2.8 | 47 | Citations (PDF) |
| 429 | Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5BRCA1 andBRCA2 mutations | 2.8 | 45 | Citations (PDF) |
| 430 | Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers | 12.4 | 615 | Citations (PDF) |
| 431 | A636P is Associated with Early-Onset Colon Cancer in Ashkenazi Jews | 0.8 | 26 | Citations (PDF) |
| 432 | Impact of germlineBRCA1mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma | 2.7 | 88 | Citations (PDF) |
| 433 | Disruption of the expected positive correlation between breast tumor size and lymph node status inBRCA1-related breast carcinoma | 2.7 | 103 | Citations (PDF) |
| 434 | Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer | 1.8 | 28 | Citations (PDF) |
| 435 | Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium | 1.6 | 41 | Citations (PDF) |
| 436 | MSI-low, a real phenomenon which varies in frequency among cancer types | 3.2 | 50 | Citations (PDF) |
| 437 | Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer | 4.1 | 54 | Citations (PDF) |
| 438 | Challenges to cancer control by screening | 34.5 | 28 | Citations (PDF) |
| 439 | Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer | 3.2 | 845 | Citations (PDF) |
| 440 | Familial Prostate and Breast Cancer in Men Treated with Prostatectomy for Prostate Cancer: A Population based Case-Control Study | 3.1 | 6 | Citations (PDF) |
| 441 | A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment | 3.4 | 269 | Citations (PDF) |
| 442 | Re: Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women | 3.2 | 0 | Citations (PDF) |
| 443 | Re: Gynecologic Surgeries and Risk of Ovarian Cancer in Women with BRCA1 and BRCA2 Ashkenazi Founder Mutations: An Israeli Population-Based Case-Control Study | 3.2 | 5 | Citations (PDF) |
| 444 | Re: Potential for Bias in Studies on Efficacy of Prophylactic Surgery for BRCA1 and BRCA2 Mutation Carriers | 3.2 | 4 | Citations (PDF) |
| 445 | Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene | 2.2 | 32 | Citations (PDF) |
| 446 | Haplotype analysis of aBRCA1: 185delAG mutation in a Chilean family supports its Ashkenazi origins | 1.5 | 16 | Citations (PDF) |
| 447 | Tamoxifen May Be an Effective Adjuvant Treatment for BRCA1-Related Breast Cancer Irrespective of Estrogen Receptor Status | 3.2 | 28 | Citations (PDF) |
| 448 | An MLH1 haplotype is over-represented on chromosomes carrying an HNPCC predisposing mutation in MLH1 | 2.2 | 12 | Citations (PDF) |
| 449 | Is there a correlation between the structure of hair and breast cancer or BRCA1/2 mutations? | 2.0 | 12 | Citations (PDF) |
| 450 | Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers | 3.2 | 330 | Citations (PDF) |
| 451 | The Founder Mutation MSH2*1906G→C Is an Important Cause of Hereditary Nonpolyposis Colorectal Cancer in the Ashkenazi Jewish Population | 4.0 | 128 | Citations (PDF) |
| 452 | Of mice and women | 28.4 | 11 | Citations (PDF) |
| 453 | Fallopian tube cancer in a BRCA1 mutation carrier: Rapid development and failure of screening | 1.9 | 17 | Citations (PDF) |
| 454 | Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms | 1.0 | 32 | Citations (PDF) |
| 455 | Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas | 2.8 | 68 | Citations (PDF) |
| 456 | Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells | 5.2 | 206 | Citations (PDF) |
| 457 | High risk genes predisposing to prostate cancer development—do they exist? | 3.1 | 20 | Citations (PDF) |
| 458 | Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives | 6.7 | 47 | Citations (PDF) |
| 459 | The Role of Genetic Factors in the Etiology of Pancreatic Adenocarcinoma: An Update | 1.1 | 28 | Citations (PDF) |
| 460 | Genetic counseling and interpretation of genetic tests in familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer | 1.2 | 22 | Citations (PDF) |
| 461 | Role of molecular diagnostic testing in familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer families | 1.2 | 17 | Citations (PDF) |
| 462 | A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes | 1.5 | 31 | Citations (PDF) |
| 463 | Prevalence of founder BRCA1
and BRCA2
mutations in unselected French Canadian women with breast cancer | 1.5 | 14 | Citations (PDF) |
| 464 | Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another | 2.7 | 102 | Citations (PDF) |
| 465 | FounderBRCA1 andBRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history | 2.8 | 40 | Citations (PDF) |
| 466 | Title is missing! | 1.6 | 14 | Citations (PDF) |
| 467 | Title is missing! | 1.1 | 16 | Citations (PDF) |
| 468 | The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40 | 1.8 | 29 | Citations (PDF) |
| 469 | Molecular Genetics of Ovarian Cancer | 1.7 | 2 | Citations (PDF) |
| 470 | Genetic mechanisms in squamous cell carcinoma of the head and neck | 1.4 | 66 | Citations (PDF) |
| 471 | Re: Magnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer | 3.2 | 106 | Citations (PDF) |
| 472 | Re: Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients | 3.2 | 5 | Citations (PDF) |
| 473 | A Comprehensive Analysis ofMNG1,TCO1,fPTC,PTEN,TSHR, and TRKA in Familial Nonmedullary Thyroid Cancer: Confirmation of Linkage to TCO1 | 3.1 | 76 | Citations (PDF) |
| 474 | Increased Risk for Nonmedullary Thyroid Cancer in the First Degree Relatives of Prevalent Cases of Nonmedullary Thyroid Cancer: A Hospital-Based Study | 3.1 | 137 | Citations (PDF) |
| 475 | Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET | 2.2 | 50 | Citations (PDF) |
| 476 | Increased Risk for Nonmedullary Thyroid Cancer in the First Degree Relatives of Prevalent Cases of Nonmedullary Thyroid Cancer: A Hospital-Based Study | 3.1 | 53 | Citations (PDF) |
| 477 | A Comprehensive Analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in Familial Nonmedullary Thyroid Cancer: Confirmation of Linkage to TCO1 | 3.1 | 29 | Citations (PDF) |
| 478 | Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer | 2.0 | 135 | Citations (PDF) |
| 479 | Increased risk of head and neck cancer in association withGSTT1 nullizygosity for individuals with low exposure to tobacco | 2.8 | 21 | Citations (PDF) |
| 480 | Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome | 8.0 | 78 | Citations (PDF) |
| 481 | An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling | 2.2 | 96 | Citations (PDF) |
| 482 | Penetrance of Mutations in the Familial Wilms Tumor Gene FWT1 | 3.2 | 19 | Citations (PDF) |
| 483 | Commentary on “Prevalence of BRCA1 and BRCA2 Mutations in Male Breast Cancer Patients in Canada” | 1.6 | 3 | Citations (PDF) |
| 484 | No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck | 4.1 | 54 | Citations (PDF) |
| 485 | True | 4.1 | 43 | Citations (PDF) |
| 486 | Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36 | 2.2 | 28 | Citations (PDF) |
| 487 | The influence of familial and hereditary factors on the prognosis of breast cancer | 8.0 | 48 | Citations (PDF) |
| 488 | Fortnightly review: Hereditary ovarian carcinoma | 0.1 | 30 | Citations (PDF) |
| 489 | A missense mutation in both hMSH2 andAPC in an Ashkenazi Jewish HNPCC kindred: implications for clinical screening | 2.2 | 24 | Citations (PDF) |
| 490 | Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours | 4.1 | 75 | Citations (PDF) |
| 491 | The effect of the I1307K APC polymorphism on the clinicopathological features and natural history of breast cancer | 4.1 | 11 | Citations (PDF) |
| 492 | An absence of founderBRCA2 mutations in individuals with squamous cell carcinoma of the head and neck 1999, 83, 803-804 | | 5 | Citations (PDF) |
| 493 | Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2 | 46.9 | 214 | Citations (PDF) |
| 494 | The Importance of a Family History of Breast Cancer in Predicting the Presence of a BRCA Mutation | 4.0 | 15 | Citations (PDF) |
| 495 | Loss of heterozygosity of methylenetetrahydrofolate reductase in colon carcinomas. | 2.2 | 10 | Citations (PDF) |
| 496 | The APC I1307K allele and breast cancer risk | 14.1 | 68 | Citations (PDF) |
| 497 | Risk factors for familial and sporadic ovarian cancer among French Canadians: A case-control study | 1.9 | 63 | Citations (PDF) |
| 498 | Is hereditary site-specific ovarian cancer a distinct genetic condition? | 0.5 | 15 | Citations (PDF) |
| 499 | Haplotype analysis of two recurrentCDKN2A mutations in 10 melanoma families: Evidence for common founders and independent mutations 1998, 11, 424-431 | | 61 | Citations (PDF) |
| 500 | I1307K APC
and hMLH1
mutations in a non-Jewish family with hereditary non-polyposis colorectal cancer | 1.5 | 7 | Citations (PDF) |
| 501 | BRCA1 and BRCA2: penetrating the clinical arena | 46.9 | 5 | Citations (PDF) |
| 502 | False family history of breast cancer in the family cancer clinic | 0.9 | 23 | Citations (PDF) |
| 503 | Linkage Analysis of Chromosome 1q Markers in 136 Prostate Cancer Families | 4.0 | 125 | Citations (PDF) |
| 504 | Founder BRCA1 and BRCA2 Mutations in French Canadian Breast and Ovarian Cancer Families | 4.0 | 164 | Citations (PDF) |
| 505 | Genetic implications of double primary cancers of the colorectum and endometrium. | 2.2 | 29 | Citations (PDF) |
| 506 | Effect of Smoking on Breast Cancer in Carriers of Mutant BRCA1 or BRCA2 Genes | 3.2 | 119 | Citations (PDF) |
| 507 | Familial Nontoxic Multinodular Thyroid Goiter Locus Maps to Chromosome 14q but Does Not Account for Familial Nonmedullary Thyroid Cancer | 4.0 | 211 | Citations (PDF) |
| 508 | The CDKN2A (p16) Gene and Human Cancer | 4.3 | 280 | Citations (PDF) |
| 509 | Excess of congenital abnormalities in French-Canadian children with neuroblastoma: A case series study from Montreal 1997, 29, 272-279 | | 19 | Citations (PDF) |
| 510 | Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women | 2.7 | 164 | Citations (PDF) |
| 511 | CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein 1997, 73, 531-536 | | 44 | Citations (PDF) |
| 512 | Polymorphisms in P21CIP1/WAF1 are not correlated with TP53 status in sporadic ovarian tumours | 2.8 | 11 | Citations (PDF) |
| 513 | Cutaneous malignant melanoma in women is uncommonly associated with a family history of melanoma in first-degree relatives: a case-control study | 1.0 | 16 | Citations (PDF) |
| 514 | Genetic Screening for Breast Cancer | 26.4 | 4 | Citations (PDF) |
| 515 | Pancreatic adenocarcinoma: epidemiology and genetics. | 2.2 | 80 | Citations (PDF) |
| 516 | Increased incidence of cancer in first degree relatives of women with double primary carcinomas of the breast and colon. | 2.2 | 12 | Citations (PDF) |
| 517 | Relative contribution should be given after each author's name | 0.1 | 9 | Citations (PDF) |
| 518 | Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study | 0.1 | 131 | Citations (PDF) |
| 519 | Relative contribution should be given after each author's name | 0.1 | 0 | Citations (PDF) |
| 520 | A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome | 0.3 | 19 | Citations (PDF) |
| 521 | MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status | 4.1 | 35 | Citations (PDF) |
| 522 | Loh and mutation analysis ofCDKN2 in primary human ovarian cancers | 2.8 | 38 | Citations (PDF) |
| 523 | Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: A case‐control study | 2.8 | 102 | Citations (PDF) |
| 524 | A somatic BRCA1 mutation in an ovarian tumour | 14.1 | 136 | Citations (PDF) |
| 525 | Family History and Risk of Ovarian Cancer | 14.4 | 4 | Citations (PDF) |
| 526 | A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1 | 2.1 | 100 | Citations (PDF) |
| 527 | Loss of heterozygosity on chromosome 5 in sporadic ovarian carcinoma is a late event and is not associated with mutations in APC at 5q21-22 | 1.0 | 30 | Citations (PDF) |
| 528 | Loss of heterozygosity on chromosome 22 in ovarian carcinoma is distal to and is not accompanied by mutations in NF2 at 22q12 | 4.1 | 40 | Citations (PDF) |
| 529 | Mutation analysis of RASK and the ‘FLR exon’ of NF1 in sporadic ovarian carcinoma | 2.8 | 8 | Citations (PDF) |
| 530 | Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma | 2.8 | 89 | Citations (PDF) |
| 531 | The expanded role of NF1 | 14.1 | 5 | Citations (PDF) |
| 532 | Breast cancer, desmold tumours, and familial adenomatous polyposis | 46.9 | 0 | Citations (PDF) |
| 533 | Tumour suppressor genes in ovarian cancer. | 0.1 | 3 | Citations (PDF) |
| 534 | Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer | 4.1 | 113 | Citations (PDF) |
| 535 | Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma | 4.1 | 118 | Citations (PDF) |
| 536 | Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. | 6.6 | 225 | Citations (PDF) |
| 537 | Genetics of cancer | 46.9 | 2 | Citations (PDF) |
| 538 | Rhabdomyolysis after intramuscular iron-dextran in malabsorption. | 6.5 | 18 | Citations (PDF) |
| 539 | Influenza A and rhabdomyolysis | 2.5 | 26 | Citations (PDF) |
| 540 | Antral Helicobacter pylori, hypergastrinaemia, and duodenal ulcers: effect of eradicating the organism. | 0.1 | 131 | Citations (PDF) |
| 541 | Renal Cancer in Hereditary Leiomyomatosis and Renal Cell Cancer: A Scoping Review of Epidemiology, Clinical Features, Management, and Outcomes | 0.4 | 1 | Citations (PDF) |
| 542 | Somatic DICER1 pathogenic variants detected in a well-differentiated fetal lung adenocarcinoma diagnosed in a man with familial adenomatous polyposis | 1.4 | 0 | Citations (PDF) |
| 543 | Towards a WHO classification of genetic tumour syndromes | 0.1 | 1 | Citations (PDF) |
| 544 | Deep intronic MSH2 variant confirms Muir-Torre subtype of Lynch syndrome | 1.6 | 1 | Citations (PDF) |
| 545 | Assessing and predicting cutaneous leiomyoma severity in hereditary leiomyomatosis and renal cell cancer syndrome: An observational study | 1.5 | 1 | Citations (PDF) |
| 546 | Comparative Transcriptome Analyses Highlight Distinct Pathogenetic Mechanisms for Pleuropulmonary Blastoma and Congenital Pulmonary Airway Malformations | 0.6 | 0 | Citations (PDF) |
| 547 | Chromophobe thyroid carcinoma: a distinct entity associated with TSC gene alterations | 1.9 | 0 | Citations (PDF) |
| 548 | Germline DICER1 variants and thyroblastoma: caution is needed in classifying variants as likely pathogenic or pathogenic | 1.9 | 0 | Citations (PDF) |
| 549 | Piloleiomyoma and renal cell carcinoma in a 30-year-old woman with hereditary leiomyomatosis and renal cell cancer syndrome | 0.8 | 0 | Citations (PDF) |
| 550 | BRCA1 and BRCA2 carriers: Perceptions of endometrial cancer risk | 2.3 | 0 | Citations (PDF) |
| 551 | Cancer risks in the Lynch syndromes | 3.2 | 1 | Citations (PDF) |
| 552 | FLCN
-Mutated Tumors in Smith-Magenis Syndrome: A Case Report of
FLCN
-Associated Pathogenesis | 0.6 | 2 | Citations (PDF) |
| 553 | Daneman Syndrome Revisited | 1.6 | 0 | Citations (PDF) |
| 554 | Piloléiomyome et carcinome à cellules rénales chez une femme de 30 ans atteinte du syndrome de léiomyomatose héréditaire associée au cancer du rein | 0.8 | 0 | Citations (PDF) |
| 555 | Rare solid tumours as indicators of hereditary cancer syndromes | 2.1 | 0 | Citations (PDF) |
| 556 | Abstract 3760: Spatial immune signatures predict outcomes in HPV-positive oropharyngeal cancer: Results of a clinical trial | 2.6 | 0 | Citations (PDF) |
| 557 | A comprehensive genomic framework for identifying genes predisposing to homologous recombination repair-deficient breast or ovarian cancer | 1.4 | 0 | Citations (PDF) |
| 558 | Causative Role for a
BRCA2
Germline Pathogenic Variant in External Auditory Canal Squamous Cell Carcinoma | 1.7 | 1 | Citations (PDF) |
| 559 | Hiding in plain sight:
DICER1
‐associated yolk sac tumour masquerading as an endometrioid carcinoma of the ovary | 2.6 | 1 | Citations (PDF) |
| 560 | Multimodal analysis of a rare BARD1 missense variant suggests its pathogenicity is conditional | 4.7 | 0 | Citations (PDF) |
| 561 | The Impact of Pathogenic Variants of BRCA1, BRCA2, and other DNA-Repair Genes on the Survival Benefits Conferred by PARP Inhibitors–Single-Centre Experience from Quebec | 0.6 | 0 | Citations (PDF) |
| 562 | 76868 Assessing Diagnostic Delays in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome: A Retrospective Cohort Study | 1.5 | 0 | Citations (PDF) |
| 563 | Abstract IA003: DICER1-related tumor predisposition: genotypes, phenotypes and mechanisms | 2.6 | 0 | Citations (PDF) |
| 564 | Comprehensive characterization of DNA polymerases driver variants using large genomic dataset | 2.7 | 0 | Citations (PDF) |
| 565 | HMGA2
is a highly sensitive marker for
DICER1
‐related tumours | 2.6 | 0 | Citations (PDF) |
| 566 | Low Prevalence of Hereditary Melanoma Among Patients Referred for Genetic Testing: A Multicentre Retrospective Cohort Study | 1.5 | 0 | Citations (PDF) |
